Magazine Article | July 1, 2021

Against All Odds: Advancing From R&D To Phase 3

Source: Life Science Leader

By Sanjeev Luther

To pave a path in a field that is bound to be riddled with disappointments, uncertainties, and sometimes even utter failure, would deter most people from creating a career in biopharma. Harrowing statistics illustrate the hardships in successfully bringing a drug to market. In fact, over 90% of compounds never even enter Phase 1 clinical trials — a number that has not changed in decades. Advancing a pharmaceutical company is an uphill battle, with many challenges along the way from data analysis to FDA regulations to trial operations and beyond.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader